4-(tert-Butoxycarbonyl-methyl-amino)-butyric acid 2,5-dioxo-pyrrolidin-1-yl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 4-(tert-Butoxycarbonyl-methyl-amino)-butyric acid 2,5-dioxo-pyrrolidin-1-yl ester
• 英文别名: (2,5-Dioxopyrrolidin-1-yl) 4-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoate；(2,5-dioxopyrrolidin-1-yl) 4-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]butanoate
• 化学式: C₁₄H₂₂N₂O₆
• 分子量: 314.338
• InChiKey: YMYQKFGUOXIYBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  93.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-benzyloxycarbonyl-L-cysteine methyl ester 、 4-(tert-Butoxycarbonyl-methyl-amino)-butyric acid 2,5-dioxo-pyrrolidin-1-yl ester 在 4-二甲氨基吡啶 、 N,N'-二环己基碳二亚胺 作用下， 生成 methyl Na-(benzyloxycarbonyl)<thio>-L-cysteinate
  参考文献：
  名称：

  New S-protection from known N-protection: thio esters of N-urethanyl-N-methyl-.gamma.-aminobutyric acid as a class of protective groups for thiols in peptide synthesis

  摘要：

  DOI：

  10.1021/jo00208a032

文献信息

• Biologically active molecules, conjugates thereof, and therapeutic uses
  申请人：REGENERON PHARMACEUTICALS, INC.

  公开号：US10570151B2

  公开（公告）日：2020-02-25

  The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule-ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.

  本公开涉及用于将生物活性分子与配体共价连接的连接体化合物。所公开的化合物还涉及生物活性分子和配体共轭物，其中生物活性分子通过连接体与配体连接。本公开进一步提供了包含生物活性分子-配体共轭物的组合物、改变异常细胞生长的方法以及使用共轭物或组合物进行治疗的方法。
• Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids
  作者：Thomas Nittoli、Marcus P. Kelly、Frank Delfino、John Rudge、Arthur Kunz、Thomas Markotan、Jan Spink、Zhaoyuan Chen、Jing Shan、Elizabeth Navarro、Michele Tait、Kathleen Provoncha、Jason Giurleo、Feng Zhao、Xiaobo Jiang、Donna Hylton、Sosina Makonnen、Carlos Hickey、Jessica R. Kirshner、Gavin Thurston、Nicholas Papadopoulos

  DOI：10.1016/j.bmc.2018.02.025

  日期：2018.5

  Natural products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs) have utilized this rich source of small molecule therapeutics to produce several clinically useful treatments. ADCs based on the natural product maytansine have been successful clinically. The authors further the utility of the anti-cancer natural product maytansine by developing efficacious payloads and linker-payloads for conjugating to antibodies. The success of our approach was realized in the EGFRvIII targeting ADC EGFRvIII-16. The ADC was able to regress tumors in 2 tumor models (U251/EGFRvIII and MMT/EGFRvIII). When compared to a positive control ADC, the efficacy observed was similar or improved while the isotype control ADCs had no effect. (C) 2018 Elsevier Ltd. All rights reserved.
• BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES
  申请人：REGENERON PHARMACEUTICALS, INC.

  公开号：US20160030591A1

  公开（公告）日：2016-02-04

  The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule-ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.
• [EN] BIOLOGICALLY ACTIVE MOLECULES, CONJUGATES THEREOF, AND THERAPEUTIC USES<br/>[FR] MOLÉCULES BIOLOGIQUEMENT ACTIVES, LEURS CONJUGUÉS, ET UTILISATIONS THÉRAPEUTIQUES
  申请人：REGENERON PHARMA

  公开号：WO2014145090A1

  公开（公告）日：2014-09-18

  The present disclosure relates to linker compounds that are useful in covalently linking biologically active molecules with Ligands. The disclosed compounds also relate to biologically active molecules and Ligand conjugates, wherein the biologically active molecule is linked to the Ligand through a linker. The disclosure further provides compositions comprising biologically active molecule -ligand conjugates, methods of modifying abnormal cell growth and methods of treatment using the conjugates or the compositions.